<ARTICLE> 5 <LEGEND> THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM IMMULOGIC PHARMACEUTICAL CORPORATION REPORT ON FORM 10K FOR THE YEAR ENDED DECEMBER 31, 1999, CONSOLIDATED STATEMENT OF NET ASSETS IN LIQUIDATION AND CONSOLIDATED STATEMENT OF CHANGES IN NET ASSETS IN LIQUIDATION AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH IMMULOGIC PHARMACEUTICAL CORPORATION ON FORM 10K FOR THE YEAR ENDED DECEMBER 31, 1999 </LEGEND> <MULTIPLIER> 1,000 <CURRENCY> U.S. DOLLARS <PERIOD-TYPE> YEAR <FISCAL-YEAR-END> DEC-31-1999 <PERIOD-START> JAN-01-1999 <PERIOD-END> DEC-31-1999 <EXCHANGE-RATE> 1 <CASH> 2,167 <SECURITIES> 0 <RECEIVABLES> 0 <ALLOWANCES> 0 <INVENTORY> 0 <CURRENT-ASSETS> 2,167 <PP&E> 0 <DEPRECIATION> 0 <TOTAL-ASSETS> 18,621 <CURRENT-LIABILITIES> 1,720 <BONDS> 0 <PREFERRED-MANDATORY> 0 <PREFERRED> 0 <COMMON> 0 <OTHER-SE> 0 <TOTAL-LIABILITY-AND-EQUITY> 0 <SALES> 0 <TOTAL-REVENUES> 0 <CGS> 0 <TOTAL-COSTS> 0 <OTHER-EXPENSES> 0 <LOSS-PROVISION> 0 <INTEREST-EXPENSE> 0 <INCOME-PRETAX> 0 <INCOME-TAX> 0 <INCOME-CONTINUING> 0 <DISCONTINUED> 0 <EXTRAORDINARY> 0 <CHANGES> 0 <NET-INCOME> 0 <EPS-BASIC> 0 <EPS-DILUTED> 0<F1> <FN> <F1>IMMULOGIC ADOPTED THE LIQUIDATION BASIS OF ACCOUNTING EFFECTIVE JULY 1, 1999 AND THEREFORE ABOVE DATA IS NOT APPLICABLE WITH THE EXCEPTION OF ASSET AND LIABILITY DATA. </FN>